Clients

Paratek Pharmaceuticals

Company Snapshot: Paratek Pharmaceuticals

PRTK
Last Change Volume High Low

Company Overview

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s lead product candidate, Omadacycline, is a novel investigational antibiotic with both once-daily intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections (UTI). A modernized tetracycline, omadacycline is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, anaerobes, atypical bacteria, and other drug-resistant strains.

Client News

  1. Feb 13 2020 Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
  2. Dec 18 2019 Paratek Awarded BARDA Project BioShield Contract for NUZYRA®
  3. Dec 18 2019 Paratek Awarded BARDA Project BioShield Contract for NUZYRA®
  4. Dec 2 2019 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)